US EditionA485 Targets EP300 in Lymphoma, Boosted by XPO1 Inhibition
Summary by BIOENGINEER.ORG
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
A485 Targets EP300 in Lymphoma, Boosted by XPO1 Inhibition
In the relentless quest to uncover new therapeutic avenues for diffuse large B-cell lymphoma (DLBCL), a recent study published in BMC Cancer sheds illuminating light on the potential of targeting the epigenetic regulator EP300. This aggressive hematological malignancy, known for its rapid progression and clinical complexity, demands innovative treatment strategies. Researchers have now identified EP300, a pivotal lysine acetyltransferase, as a p…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage